Others have already posted good stuff on how apabetalone affects ALP. I'll add a few more resources.

Here's a great presentation by BETonMACE Clinical Steering Committee member Dr. Kam Kalantar-Zadeh from last year's ERA-EDTA symposium that covers this in depth.

Also here is a presentation by Dr. Marta Ruiz-Ortega from this year's ERA-EDTA that covers epigenetic mechanisms targeting ALP.

Plus there's this paper:

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease

And there's this paper:

Apabetalone downregulates factors and pathways associated with vascular calcification

More to the story should be published soon. From the recent filings "We have submitted  a  manuscript titled  “Apabetalone  Lowers  Serum  Alkaline  Phosphatase  and  Improves  Cardiovascular  Risk  in Patients  with  Cardiovascular  Disease”,  led  and  written  in  collaboration  with  clinical  experts  in  the  area  ALP  and  CKD,  This publication has  been  re-submitted  with  requested  edits  to  Atheroslcerosis.  Data  contained  in  this  manuscript  highlights  the  role of  ALP  in cardiovascular  risk,  and  the  benefits  of  apabetalone  induced  reduction of  ALP  in reducing  cardiovascular  risk  in treated  CVD  patients."